The legal action, filed by Hagens Berman Sobol Shapiro LLP, targets a period between April 16, 2025, and May 4, 2026. Plaintiffs allege that GeneDx executives promoted the acquisition of Fabric Genomics as an AI-driven catalyst for growth and software-based revenue, while concealing significant operational disconnects and integration failures. These internal hurdles reportedly compromised the company's financial performance throughout the class period.

The facade of synergy crumbled on May 4, 2026, when GeneDx released first-quarter results that missed revenue estimates and forced a sharp reduction in full-year guidance. The company disclosed a $31.2 million impairment charge related to the Fabric unit—effectively erasing 94% of the original acquisition cost. Investors reacted to the news by offloading shares, causing the stock price to plunge from $67.93 to $34.51 in one trading session. Reed Kathrein, the Hagens Berman partner overseeing the investigation, stated that the firm is scrutinizing the full scope of management's public claims regarding the supposed AI efficiencies that never materialized.